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ABSTRACT 
SET-M33 is a multimeric antimicrobial peptide active against Gram-negative bacteria in vitro and 
in vivo. Insights into its killing mechanism could elucidate correlations with selectivity.  
SET-M33 showed concentration-dependent bactericidal activity against colistin-susceptible and 
resistant isolates of P. aeruginosa and K. pneumoniae. Scanning and transmission microscopy 
studies showed that SET-M33 generated cell blisters, blebs, membrane stacks and deep craters in K. 
pneumoniae and P. aeruginosa cells. NMR analysis and CD spectra in the presence of sodium 
dodecyl sulfate micelles showed a transition from an unstructured state to a stable α-helix, driving 
the peptide to arrange itself on the surface of micelles. 
SET-M33 kills Gram-negative bacteria after an initial interaction with bacterial LPS. The molecule 
becomes then embedded in the outer membrane surface, thereby impairing cell function. This 
activity of SET-M33, in contrast to other similar antimicrobial peptides such as colistin, does not 
generate resistant mutants after 24 h of exposure, non-specific interactions or toxicity against 
eukaryotic cell membranes, suggesting that SET-M33 is a promising new option for the treatment 
of Gram-negative antibiotic-resistant infections. 
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INTRODUCTION 
Extensive use of broad-spectrum antibiotics has led to the development and spread of extensively 
antibiotic-resistant strains of bacteria, making antimicrobial resistance a global problem. Antibiotic-
resistant bacteria kill 25,000 people in the EU every year. Infections such as urinary tract infections 
[1], pneumonia [2] and septicemia [3] are increasingly associated with multi-drug resistant Gram-
negative bacteria in all regions of the world [4]. These antibiotic-resistant bacteria generally cause 
infections associated with increased risk of poor clinical outcome and mortality compared to non-
resistant strains of the same bacteria [5]. The World Health Organization warns that antimicrobial 
resistance is an increasingly serious threat to global public health and calls for action across all 
government sectors and society [6] to avoid a dreaded “post-antibiotic” era. 
A recent rekindling of antibiotic research has shown that the antimicrobial peptide class of 
antibiotics is particularly promising for use against infections caused by multidrug-resistant 
microorganisms [7-9]. Antimicrobial peptides (AMPs) are an important component of the natural 
defenses of most living organisms, and more than 2500 AMPs have been registered in the 
Antimicrobial Peptide Database (http://aps.unmc.edu/AP/main.php) [10].
 
However, despite their 
desirable characteristics, antimicrobial peptides have had limited pharmaceutical development due 
to their toxicity, instability and manufacturing costs, and therefore only a few AMPs have actually 
been approved for clinical use [11-12]. 
The most common mechanism of antimicrobial killing by antimicrobial peptides is disruption of the 
cytoplasmic membrane, for example by pore formation, which is rather non-specific but highly 
efficient [13-15]. Alternative mechanisms of action include peptide translocation into the cytoplasm 
where the antibiotic interferes with bacterial metabolic processes, such as protein synthesis or DNA 
replication, while other peptides are known to interact directly with specific membrane components 
[16-18]. In particular, cationic AMPs have been demonstrated to induce anionic lipid clustering 
which appears to arrest bacterial growth or trigger cell death [19-20]. 
SET-M33 is an antimicrobial peptide that has been extensively studied in recent years [21-25]. It is 
a cationic non-natural peptide built in a branched form (Figure 1) that makes it more resistant to 
degradation in biological fluids [26]. SET-M33 has shown efficacy against a number of Gram-
negative multi-drug and extensively drug-resistant clinical isolates [21, 24]. It has also shown 
acceptable toxicity in human cells and in mice [22], as well as anti-inflammatory activity [23]. 
Nevertheless, its mechanism of action has not yet been researched in depth. In this study we used 
different techniques to study the mechanism of action of SET-M33 against two Gram-negative 
bacterial species, K. pneumoniae and P. aeruginosa: 1) bacterial killing kinetics over time to see 
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concentration-dependency and onset of resistance; 2) electron microscopy imaging of treated 
bacteria to visualize membrane disturbance; 3) hemolytic activity to assess eukaryotic cell toxicity 
and 4) NMR and circular dichroism to study the structure of the peptides in the presence of micelles 
and their ability to stabilize in a facial amphiphilic helix. 
 
Figure 1. Structure of SET-M33 
 
MATERIALS AND METHODS 
Peptide synthesis 
All peptides were prepared by solid-phase synthesis through standard Fmoc chemistry using a Syro 
multiple peptide synthesizer (MultiSynTech, Witten, Germany). Side chain protecting groups were 
2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl for R, t-butoxycarbonyl for K and t-butyl for S 
(Iris Biotech GmbH, Marktredwitz, Germany). The final products were cleaved from the solid 
support, de-protected by treatment with TFA containing triisopropylsilane and water (95/2.5/2.5), 
and precipitated with diethyl ether. Final peptide purity and identity was confirmed by reverse-
phase chromatography on a Phenomenex Jupiter C18 analytical column (300 Å, 250 x 4.6 mm) and 
by mass spectrometry. 
Q-33 (linear peptide, QKKIRVRLSA) was produced on TentaGel S RAM resin (Iris Biotech 
GmbH, Marktredwitz, Germany). The crude peptide, released as amide, was purified by reverse-
phase chromatography on a Phenomenex Jupiter C18 column (300 Å, 250 x 10 mm), in a linear 
gradient, using 0.1% TFA/water as eluent A and acetonitrile as eluent B (from 99% to 50% of A in 
30 min). The compound was characterized on a MALDI-TOF mass spectrometer (Ultraflex III 
Bruker Daltonics): QKKIRVRLSA-NH2, MALDI-MS: 1198.97 [M+H]+; RP-HPLC: tR = 19.62 
min, purity >99%. 
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SET-M33 (tetrabranched peptide, (KKIRVRLSA)4K2K) was synthesized on a Fmoc4-
Lys2-Lys--Ala Wang resin (Iris Biotech GmbH, Marktredwitz, Germany). The crude peptide, 
released as carboxylic acid, was purified by reverse-phase chromatography on a Phenomenex 
Jupiter C18 analytical column (300 Å, 250 x 10 mm) in a linear gradient, using water with 0.1% 
TFA as eluent A and acetonitrile as eluent B (from 82% to 75% of A in 60 min). The purified 
peptide was obtained as a trifluoroacetate salt and exchanged to acetate using a quaternary 
ammonium resin (AG1-X8, 100–200 mesh, 1.2 meq/ml capacity). The resin-to-peptide ratio was 
2000:1, resin and peptide were stirred for 1 h, the resin filtered off, washed extensively and the 
peptide recovered and freeze-dried. The compound was characterized on a MALDI-TOF mass 
spectrometer (Ultraflex III Bruker Daltonics): (KKIRVRLSA)4K2KMALDI-MS: 4682.48 
[M+H]+; RP-HPLC: tR = 21.10 min, purity >99%. SET-M33 solubility, water ≥ 20mg/ml, saline ≥ 
20mg/ml, PBS ≥ 15mg/ml. 
 
Selection of colistin-resistant mutants of K. pneumoniae R-DYK 4861 and P. aeruginosa B-162  
K. pneumoniae R-DYK 4861 and P. aeruginosa B-162 were both extensively antibiotic-resistant 
clinical isolates and colistin-susceptible. Colistin-resistant mutants of both strains were obtained by 
step-wise serial passages of bacterial strains [27] in BBL™ Mueller Hinton II (MH-II) broth 
(Becton, Dickinson Benelux N.V., Erembodegem, Belgium) containing colistin concentrations in 
the range 2–64 mg/L (colistin sulfate, Sigma-Aldrich Chemie BV, Zwijndrecht, the Netherlands). 
This involved sub-culturing 100 µl of overnight culture of the bacteria (grown in MH-II broth) into 
MH-II broth containing 2 mg/L colistin and incubating overnight at 35ºC. In subsequent steps 100 
µl of overnight culture was sub-cultured into MH-II broth containing two-fold increases in the 
concentration of colistin until the highest colistin concentration of 64 mg/L was achieved. Finally, 
100 µl volumes were sub-cultured onto solid MH-II medium (Becton, Dickinson Benelux N.V., 
Erembodegem, Belgium). Colistin-resistant colonies were then characterized phenotypically using 
VITEK® 2. 
Phenotypic characterization of bacterial isolates 
Phenotypic characterization of K. pneumoniae B-DYK 4861 and P. aeruginosa B-162 isolates and 
their colistin-resistant mutants was performed by determining their susceptibility for a panel of 18 
different antibiotics from the main classes of antibiotics using the VITEK® 2 antimicrobial 
identification system (BioMérieux Benelux BV, Zaltbommel, The Netherlands) and AST-N140 
cards (Vitek AMS). Interpretation of antimicrobial susceptibility was based on EUCAST 2014 
guidelines [28]
 
(Table 1S Supplementary data). 
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Antimicrobial susceptibility of bacterial isolates - MIC assay 
Antimicrobial susceptibility was assessed by determining the Minimum Inhibitory Concentration 
(MIC) of SET-M33 and colistin using the broth microdilution technique according to 2014 
EUCAST guidelines. The MIC assay measures visible inhibition of bacterial growth after 24 h 
exposure of bacteria to antibiotic in MH-II broth. The two-fold antibiotic concentration range used 
for SET-M33 and colistin was 0.063–64 mg/L. 
Concentration- and time-dependent bactericidal activity of SET-M33 and colistin – TKK 
assay  
The concentration- and time-dependent killing capacity of SET-M33 was determined using time-
kill kinetic (TKK) assays, as previously described [29].
 
Briefly, stationary-phase MH-II broth 
cultures of K. pneumoniae R-DYK 4861 and P. aeruginosa B-162 were diluted in 25 ml MH-II 
broth until a density of approximately 7×10
5
 colony forming units (CFU/ml) was achieved. 
Bacterial cultures were exposed to antimicrobial antibiotics at 2-fold increasing concentrations for 
24 h at 37°C under shaking conditions at 96 rpm at 37ºC. Next, 1 mL samples were taken at 0, 1, 2, 
4, 6 and 24 h of antibiotic exposure and centrifuged at 12500 xg for 5 min to pellet the cells, which 
were then resuspended in sterile PBS. Agar plates were incubated for 24 h (K. pneumoniae) or 48 h 
(P. aeruginosa) at 37C in order to determine the number of CFU. The lower limit of quantification 
in this assay was 5 CFU/mL (log 0.7). For colistin-susceptible bacterial isolates, the two-fold 
antibiotic concentration range was 0.125–64 mg/L for SET-M33 and colistin alike. For colistin-
resistant isolates, the two-fold antibiotic concentration range was 0.125–64 mg/L for SET-M33 and 
1–512 mg/L for colistin. Flasks showing re-growth of bacteria after 24 h antibiotic exposure were 
examined for changes in antibiotic susceptibility using the antibiotic MIC assay described above, 
but with an antibiotic concentration range of 0.5–512 mg/L for the colistin-resistant isolates. 
Sample preparation for electron microscopy 
P. aeruginosa PAO1 and K. pneumoniae ATCC 13833 cells in logarithmic phase were resuspended 
at 2 × 10
8
 CFU/ml in PBS and incubated with 1.5 µM SET-M33 at room temperature for 15, 30 and 
60 min. The mixture was then centrifuged for 5 min at 10 000 r.p.m.  
Scanning electron microscopy 
Centrifuged bacteria were resuspended in 500 µl PBS and a drop of liquid cell suspension was 
placed on untreated glass coverslip for five minutes. The coverslip was then fixed for immersion in 
2.5% glutaraldehyde solution in phosphate buffer 0.1 M pH 7.2 (PB) for 2 h at 4°C, washed in PB, 
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postfixed in 1% OsO4 in PB for 30 min at 4°C, dehydrated in an ascending alcohol series, and dried 
in a Balzers CPD 030 CO2 critical point dryer.  
The coverslip was then mounted on an aluminum stub, coated with 20 nm gold in a Balzers 
MED010 sputtering device, and observed in a Philips XL20 scanning electron microscope with an 
electron accelerating voltage of 20 kV. 
Transmission electron microscopy 
Centrifuged bacteria were fixed in 2.5% glutaraldehyde solution in phosphate buffer 0.1 M pH 7.2 
(PB) for 2 h at 4°C, washed in PB, post-fixed in 1% OsO4 in PB for 30 min at 4°C, dehydrated in an 
ascending alcohol series, incubated twice in propylene oxide and finally infiltrated and embedded in 
epon/araldite resin that was polymerized at 60°C for 48 h. 
Ultrathin sections (60 nm thick) were cut from samples on a Reichert-Jung Ultracut E 
ultramicrotome, mounted on 200-mesh copper grids, stained with uranyl acetate and lead citrate and 
observed in a FEI Technai G2 SPIRIT transmission electron microscope using an electron 
accelerating voltage of 100 kV under standard operating conditions.  
Nuclear magnetic resonance 
All NMR samples were prepared by dissolving lyophilized peptides in 500 µl H2O/D2O (95:5) to a 
final concentration of 1.0 mM, with the exception of SET-M33, which was dissolved to a final 
concentration of 0.25 mM. Since the resonance of N-terminus amide would be missed in aqueous 
media due to chemical exchange, the peptide sequence of the Q-33 peptide, bearing a leading 
glutamine [33-34],
 
was used instead, allowing us to gain structural information on the Lys1 residue. 
Samples with micelles were prepared using 100 mM fully deuterated sodium dodecyl sulfate (SDS-
d25, Cambridge Isotopes). Paramagnetic spectra were recorded with 2.5 mM Gd(III)(DTPA-BMA). 
All spectra were acquired on a Bruker DRX Avance spectrometer operating at 14.1 Tesla at a 
temperature of 298 K. Two-dimensional spectra were recorded by accumulating 32 FIDs for 512 
experiments, digitalizing over 2048 points. Spectral width was set at 6000 Hz and repetition delay 
at 3 s. The mixing time for total correlation spectroscopy (TOCSY) and nuclear Overhauser 
spectroscopy (NOESY) spectra was set at 45/75 ms and 100/200/ 300 ms, respectively. All spectra 
were processed to a final size of 2048 by 1024 points. Peak assignment and integration were carried 
out with Sparky software (T. D. Goddard and D. G. Kneller, SPARKY 3, University of California, 
San Francisco) while calibration of NOE peak volumes, distance calculation and restrained torsion 
angle dynamics for structure calculation were performed using Dyana [30].
 
Circular dichroism 
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CD spectra were recorded at 25°C with a Jasco 815 spectropolarimeter using quartz cells having a 
path length of 0.1-cm. SET-M33 (100 M) or Q-33 (100 M) were dissolved in pure water or 30 
mM SDS. The results were processed with the application Spectra Manager II™ Suite . 
Hemolytic activity 
The ability of SET-M33 peptide to induce hemolysis of human red blood cells was assessed. Whole 
blood (EDTA) was centrifuged (1100 xg) for 10 min. Red blood cells diluted 1:100 in PBS were 
incubated for 24 h at 37°C in PBS with two-fold serial dilution of all peptides from 4 mg/L to 1.8 
g/L. The absorbance of the supernatants was determined in a 96-well plate at 490 nm using a 
microplate reader. Date for 100% hemolysis was obtained by adding 0.1% Triton X-100 in water. 
The negative control was PBS. The hemolysis rate of each peptide was calculated with the 
following equation: Hemolysis (%) = (Apeptide-APBS)/(Atriton-APBS) x 100%; were A=absorbance. 
FPLC-gel filtration 
LPS from P. aeruginosa (ATCC 27316, Sigma Aldrich) and SET-M33 was gel-filtered on a 
Superdex 75 10/300 GL fast protein liquid chromatography column using an AKTA Purifier (GE 
Healthcare) in PBS pH 7.4. 100 µl of 2 g/l SET-M33 or 13 g/l LPS or 13 g/l LPS + 2 g/l SET-M33 
was injected on a Superdex 75 10/300 GL column with a flow rate of 0.75 ml/min and absorbance 
was measured at 220 and 260 nm. 
 
 
RESULTS AND DISCUSSION 
The K. pneumoniae and P. aeruginosa isolates used in the following experiments were resistant to a 
wide range of beta-lactam antibiotics (penicillins, cephalosporins and carbapenems) including the 
4
th
 generation cephalosporin cefepime, aminoglycosides (gentamycin and tobramycin) and 
fluoroquinolones (ciprofloxacin and norfloxacin). Interpretation of antimicrobial susceptibility was 
based on European Committee on Antimicrobial Susceptibility Testing (EUCAST) 2014 guidelines 
[28].
 
Susceptibility of bacterial isolates to SET-M33 and colistin – minimum inhibitory 
concentration MIC  
The susceptibility of the colistin-susceptible K. pneumoniae B-DYK 4861 and P. aeruginosa B-162 
isolates and their colistin-resistant mutants to SET-M33 and colistin in terms of MIC are shown in 
Table 1.
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Table 1. MICs of SET-M33 and colistin for bacterial isolates in triplicate 
Bacterial isolate colistin-
susceptible 
K. pneumoniae 
R-DYK 4861 
colistin-
resistant 
K. pneumoniae 
R-DYK 4861 
colistin-susceptible 
P. aeruginosa 
B-162 
colistin-resistant 
P. aeruginosa 
B-162 
AMP median range median range median range median range 
SET-M33 mg/L 16 16–16 16 16–32 16 8–16 16 8–16 
μM 2.7 2.7–2.7 2.7 2.7–5.5 2.7 1.4–2.7 2.7 1.4–2.7 
Colistin mg/L 0.50 0.25–0.50 >512 >512 2 2–2 512 128–512 
μM 0.22 0.11–0.22 >222 >222 0.87 0.87–0.87 222 55–222 
Colistin resistance did not affect SET-M33 susceptibility in these two strains, confirming our 
previous data on seven different colistin-resistant K. pneumoniae strains [21].
 
SET-M33 showed a MIC of 8 mg/L for K. pneumoniae ATCC 13833 and P. aeruginosa PAO1 
[21]. 
 
SET-M33 and colistin activity against colistin-susceptible and colistin-resistant K. pneumoniae 
B-DYK 4861 and P. aeruginosa B-162 – time-kill-kinetics TKK 
The major killing effect of an antibiotic against an organism depends on the exposure time or 
concentration of the drug at the active target site. In the present study we investigated extensively 
drug-resistant K. pneumoniae and P. aeruginosa populations, taking the effects of exposure time 
and concentration into account.  
Colistin-susceptible and colistin-resistant K. pneumoniae isolates were killed by ≥99.9% after 2 h of 
exposure to ≥4 mg/L and ≥8 mg/L SET-M33, respectively (the first concentration above the grey 
shade in Figure 2A, B). This was followed by bacterial re-growth up to the level of non-exposed 
bacteria after 24 h exposure to ≤4 mg/L and ≤16 mg/L, respectively. Colistin killed ≥99.9% of the 
colistin-susceptible K. pneumoniae isolate after 2 h of exposure to ≥0.5 mg/L (Figure 2C) and 
bacterial re-growth after 24 h exposure was observed up to ≤32 mg/L. 
In the colistin-resistant isolate, colistin concentration-dependent killing was observed in the first 
hour of exposure but ≥99.9% killing was not achieved after 2 h of exposure (Figure 2D).  
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Figure 2. Concentration- and time-dependent bactericidal activity of SET-M33 and colistin against 
isolates of K. pneumoniae R-DYK 4861 (A-D) and P. aeruginosa B-162 (E-H). Bacterial cultures 
were exposed to two-fold increasing concentrations of SET-M33 or colistin for 24 h at 37
o
C under 
shaking conditions. Samples were collected at 1, 2, 4, 6 and 24 h, and after centrifuging and 
washing, were sub-cultured onto antibiotic-free solid media to determine CFU counts after 
incubation for 24 h at 37
o
C. Data are medians of 3 experiments. Grey shading indicates ≥99.9% 
killing achieved after 2 h of exposure.  
 
0 1 2 3 4 5 6
0
1
2
3
4
5
6
7
8
9
10
24
control
1 mg/L
2 mg/L
4 mg/L
8 mg/L
16 mg/L
32 mg/L
64 mg/L
128 mg/L
256 mg/L
512 mg/L
Time (hours)
lo
g
 C
F
U
/m
l
0 1 2 3 4 5 6
0
1
2
3
4
5
6
7
8
9
10
24
control
0.125 mg/L
0.25 mg/L
0.5 mg/L
1 mg/L
2 mg/L
4 mg/L
8 mg/L
16 mg/L
32 mg/L
64 mg/L
Time (hours)
lo
g
 C
F
U
/m
l
0 1 2 3 4 5 6
0
1
2
3
4
5
6
7
8
9
10
24
control
0.125 mg/L
0.25 mg/L
0.5 mg/L
1 mg/L
2 mg/L
4 mg/L
8 mg/L
16 mg/L
32 mg/L
64 mg/L
Time (hours)
lo
g
 C
F
U
/m
l
A B
C D
0 1 2 3 4 5 6
0
1
2
3
4
5
6
7
8
9
10
24
control
0.125 mg/L
0.25 mg/L
0.5 mg/L
1 mg/L
2 mg/L
4 mg/L
8 mg/L
16 mg/L
32 mg/L
64 mg/L
Time (hours)
lo
g
 C
F
U
/m
l
0 1 2 3 4 5 6
0
1
2
3
4
5
6
7
8
9
10
24
control
0.125 mg/L
0.25 mg/L
0.5 mg/L
1 mg/L
2 mg/L
4 mg/L
8 mg/L
16 mg/L
32 mg/L
64 mg/L
Time (hours)
lo
g
 C
F
U
/m
l
0 1 2 3 4 5 6
0
1
2
3
4
5
6
7
8
9
10
24
control
1 mg/L
2 mg/L
4 mg/L
8 mg/L
16 mg/L
32 mg/L
64 mg/L
128 mg/L
256 mg/L
512 mg/L
Time (hours)
lo
g
 C
F
U
/m
l
0 1 2 3 4 5 6
0
1
2
3
4
5
6
7
8
9
10
24
control
0.125 mg/L
0.25 mg/L
0.5 mg/L
1 mg/L
2 mg/L
4 mg/L
8 mg/L
16 mg/L
32 mg/L
64 mg/L
Time (hours)
lo
g
 C
F
U
/m
l
0 1 2 3 4 5 6
0
1
2
3
4
5
6
7
8
9
10
24
control
0.125 mg/L
0.25 mg/L
0.5 mg/L
1 mg/L
2 mg/L
4 mg/L
8 mg/L
16 mg/L
32 mg/L
64 mg/L
Time (hours)
lo
g
 C
F
U
/m
l
E F
G H
Colistin-susceptible K. pneumoniae
SET-M33
Colistin-resistant K. pneumoniae
SET-M33
Colistin-susceptible K. pneumoniae
colistin
Colistin-resistant K. pneumoniae
colistin
Colistin-susceptible P. aeruginosa
SET-M33
Colistin-resistant P. aeruginosa
SET-M33
Colistin-susceptible P. aeruginosa
colistin
Colistin-resistant P. aeruginosa
colistin
(MIC)
(MIC)
(MIC)
(MIC) (MIC)
(MIC)
(MIC)
(MIC)
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
11 
 
For P. aeruginosa, ≥99.9% killing was achieved in colistin-susceptible and colistin-resistant isolates 
after 2 h of exposure to ≥8 mg/L SET-M33 (Figure 2E and 2F). 
Colistin killed ≥99.9% of bacteria in the colistin-susceptible P. aeruginosa isolate after 2 h of 
exposure to a concentration ≥1 mg/L (Figure 2G). In the colistin-resistant P. aeruginosa isolate, 
colistin concentration-dependent killing was observed in the first 2 h of exposure, followed by 
bacterial re-growth up to the level of non-exposed bacteria after 24 h, at all the colistin 
concentrations tested (Figure 2H).  
We also showed that exposure to SET-M33 sterilized colistin-susceptible K. pneumoniae and P. 
aeruginosa populations already at one-fold (16 mg/L) (Figure 2A) and four-fold (64 mg/L) (Figure 
2E) the MICs, respectively. In contrast, after exposure to colistin, sterilization only occurred at the 
extremely high concentration of 64 mg/L (Figure 2C and 2G), which is 128-fold and 32-fold the 
MICs of colistin-susceptible K. pneumoniae and P. aeruginosa, respectively. Colistin-resistant K. 
pneumoniae and P. aeruginosa were sterilized with 64 mg/L SET-M33 (Figure 2B and 2F)  in both 
cases (four-fold the MIC) but never with colistin (Figure 2D and 2H). 
SET-M33 and colistin showed concentration-dependent bactericidal activity against colistin-
susceptible and colistin-resistant isolates of K. pneumoniae and P. aeruginosa. This result is similar 
to the action of different widely used antibiotics e.g. aminoglycosides and fluoroquinolones, as well 
as other AMPs [31].
 
SET-M33 retains activity against both colistin-susceptible and colistin-resistant bacteria. This result 
indicates that SET-M33 is impervious to the mechanisms associated with colistin resistance.  
 
Selection of resistance 
Selection of resistance was assessed in the same experiments: when re-growth was observed after 
24 h of exposure to antibiotic, bacterial susceptibilities were determined as MIC. Re-growth of 
colistin-susceptible strains of K. pneumoniae and P. aeruginosa after 24 h of exposure to SET-M33 
was never associated with selection of SET-M33 resistance (Table 2): in fact, MIC values did not 
increase more than 0.5-2 fold, whereas re-growth of K. pneumoniae after 24 h of colistin exposure 
was associated with decreased susceptibility and a manifold increase in MIC (Table 2). Colistin was 
more effective against P. aeruginosa, although bacteria regrowing at 1 mg/L colistin showed a ~six-
fold increase in MIC.  
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Similar results were obtained with the colistin-resistant strains, although re-growth of colistin-
resistant K. pneumoniae showed slightly lower susceptibility to SET-M33 with a four-fold increase 
in MIC (Table 2S Supplementary data). 
 
Table 2. Change in colistin-susceptible K. pneumoniae R-DYK 4861 and P. aeruginosa B-162 
susceptibility to SET-M33 and colistin after 24 h exposure to antibiotic as determined by MIC assay 
Antibiotic 
concentration 
(mg/L) 
SET-M33 (mg/L) Colistin (mg/L) 
colistin-susceptible 
K. pneumoniae 
colistin-susceptible 
P. aeruginosa 
colistin-susceptible 
K. pneumoniae 
colistin-susceptible 
P. aeruginosa 
control 16 16 0.5 2 
0.125 16 16 >64 2 
0.25 16 16 >64 2 
0.5 16 16 >64 4 
1 16 16 >64 12
1
 
2 16 16 >64 NR 
4 32 16 >64 NR 
8 NR 16 64
1
 NR 
16 NR 12
1
 >64
2
 NR 
32 NR NR >64
1
 NR 
64 NR NR NR NR 
Colistin-susceptible bacterial cultures were exposed to two-fold increasing concentrations of SET-
M33 or colistin for 24 h at 37
o
C under shaking conditions. When bacteria re-grew after 24 h 
exposure to antibiotic, their MIC susceptibilities (performed in triplicate) were also determined and 
the median value reported. NR, no bacterial re-growth.
 
1
 One out of three samples did not show bacterial re-growth. 
2
 Two out of three samples did not show bacterial re-growth. 
 
Gram-negative bacteria can reduce their susceptibility to AMPs by reducing their net negative 
surface charges, modifying capsule polysaccharides, or reducing outer membrane fluidity [32]. In 
contrast to colistin, resistance to SET-M33 does not readily develop during 24 hours of continuous 
exposure. This finding provides evidence that some of the resistance mechanisms that affect colistin 
do not affect SET-M33 to the same extent. For example, the mutations that lead to colistin 
resistance may not have the same effect on the activity of SET-M33, or alternatively, exposure to 
SET-M33 may not elicit the type of resistance mutations that are selected or induced by colistin. 
Ways of avoiding resistance will be investigated in further studies. Importantly, the fact that 
resistance to SET-M33 does not appear within 24 exposure period to the antibiotic provides 
evidence that the use of SET-M33 in the clinic may have advantages over the use of colistin. For 
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example, colistin is currently used as an antibiotic of last resort for MDR bacteria [33-34], but 
besides its toxic side effects, it is also becoming dangerously more often ineffective due to 
increasing number of resistant strains [35-37]. 
 
Electron microscopy 
The effect of SET-M33 treatment at MIC (8 mg/L SET-M33) for 15, 30 and 60 min on bacterial 
cell morphology was studied by scanning electron microscopy (SEM) and transmission electron 
microscopy (TEM). SEM images showed that after 30 min of SET-M33 treatment, the surfaces of 
K. pneumoniae ATCC 13833 and P. aeruginosa PAO1 cells lost their smoothness and developed 
superficial blisters (Figure 3). After 60 min of SET-M33 treatment, bacterial cells appeared larger 
than control cells and many were empty and showed large holes, mainly at the poles. 
A B C
D E F
 
Figure 3. Scanning electron micrographs (SEM) of K. pneumoniae ATCC 13833 and P. aeruginosa 
PAO1. SEM micrographs of A) untreated K. pneumoniae; B) K. pneumoniae after 30 min 
incubation with SET-M33 at MIC; C) K. pneumoniae after 60 min incubation with SET-M33 at 
MIC; D) untreated P. aeruginosa; E) P. aeruginosa after 30 min incubation with SET-M33 at MIC; 
F) P. aeruginosa after 60 min incubation with SET-M33 at MIC. Scale bar 2 µm. 
 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
14 
 
TEM microscopy (Figure 4) showed significant signs of alteration in most bacterial cells after 30 
min of SET-M33 treatment: P. aeruginosa and K. pneumoniae cells appeared turgid and 
filamentous material appears on the external side of the outer membrane. 
. 
 
Figure 4. Transmission electron micrographs (TEM) of K. pneumoniae ATCC 13833 and P. 
aeruginosa PAO1. TEM micrographs of A) untreated K. pneumoniae; B) K. pneumoniae after 60 
min incubation with SET-M33 at MIC; C) untreated P. aeruginosa; D) P. aeruginosa after 60 min 
incubation with SET-M33 at MIC. Scale bar 500 nm. 
 
In the first 30 minutes after incubation with SET-M33, only a few K. pneumoniae and P. aeruginosa 
bacterial cells (rare in the micrograph field) showed cell damage. 
A B
C D
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Some linear peptides are reported to kill bacteria very quickly [16], while others, such as magainin-
2, kill bacteria after 15-90 min. SET-M33 damages bacteria in the latter time range: indeed 
microscopy only showed initial signs of bacterial membrane disturbance in very few cells after 10-
15 min of exposure. With longer exposure, the damage to bacterial membranes increased in 
frequency and severity.  
 
Peptide conformation – NMR structure analysis and circular dichroism 
The supramolecular structure of peptides is important and has been extensively studied in 
interactions of peptides with bacterial membranes [16, 38-39].
 
The NMR spectra of free SET-M33 
showed a chemical shift index typical of a random coiled conformation and no significant inter-
residue NOEs, indicating that the peptide explores a large conformational space. On addition of 
sodium dodecyl sulfate (SDS) micelles, the NMR spectrum of SET-M33 undergoes a generalized 
broadening, caused by the production of slow-tumbling high-mass species, precluding further 
analysis. The high-mass species could be aggregates of SET-M33-SDS, possibly promoted by the 
multimericity of SET-M33. We therefore synthesized an analogue peptide, Q-33, in linear form and 
capped it with an additional amino acid (Q-KKIRVRLSA) at the N-terminus in order to generate a 
model of SET-M33 that could be studied in the presence of SDS. Q-33 has an extremely lower half 
life in serum and plasma than SET-M33, 2 hours versus 24 hours, and consistently it has a lower 
activity against Gram-negative bacteria [40-41]. The additional Q allowed us to study the structure 
of all residues, including the first lysine. Q-33 did not show any stable conformation in water, but 
addition of SDS micelles caused a generalized dispersion of proton resonances and the emergence 
of NOE peaks, indicating that a stable conformer was present as a consequence of the peptide-
micelle interaction. In particular, NOE signals of the Hαi-HNi+3, Hαi-Hβi+3 and HNi-HNi+2 types for 
residue i=1 to 6 are diagnostic of α-helix conformation spanning residues 1-9 (Figure 5A). Peak 
integration of a total set of 32 NOEs allowed us to calculate the relative interproton distances, 
which were used as constraints for simulation of torsion angle dynamics and subsequent peptide 
structure calculations. The resulting structure showed a regular α-helix encompassing the full-length 
of the peptide. 
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Figure 5. A) NOESY spectrum of Q-33 peptide in the presence of SDS micelles showing the Hα-
HN correlation path typical of α-helices. B) Structural model of peptide conformation and 
interaction geometry with micelle surface (dashed line) as derived from NMR data, attenuation 
values A obtained by adding the soluble paramagnetic probe Gd(III)(DTPA-BMA) to the 
peptide/SDS sample are reported in the upper part. C) CD spectrum of SET-M33 100 M in water 
and SDS 30 mM. D) CD spectrum of Q-33 100 M in water and SDS 30 mM. 
 
To assess the interaction geometry of the helix with SDS micelles, a paramagnetic solution-NMR 
experiment was performed. TOCSY (total correlation spectroscopy) spectra of the peptide-micelle 
system were acquired in the presence and absence of increasing concentrations of the paramagnetic 
probe Gd(III)(DTPA-BMA). The soluble probe causes nuclear spin relaxation proportional to the 
local surface accessibility of the molecule investigated [42-44].
 
Relaxation is measured by 
calculating the decrease in peak volumes on addition of the probe, and is summarized as a bare 
number, the attenuation value A, which ranges from 0 to 2 and can be determined for each known 
proton peak. Protons shielded by contact with the solvent, and therefore not accessible to the probe, 
show low A values, while exposed protons show high A values (Figure 5B, upper part). Attenuation 
analysis was carried out on the Q-33-micelle system and an accurate accessibility profile was 
determined. Residues I3 and L7 showed much lower accessibility of the probe to their sidechains, 
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and this can be ascribed to shielding by close interaction with the micelle surface. Charged residue 
pairs K1/R4 and K2/R6, situated on the opposite side of the helix, showed a higher A value, while 
V5 and S8 showed the highest attenuation due to their high exposure to the solvent. The resulting 
structure was a helix lying on the micelle surface with I3/L7 sidechains inserted into the SDS 
assembly, and R and K sidechains arranged parallel to the surface, their charged tips interacting 
with the negative sulfate groups (Figure 5B). This facial amphiphilic structure has already been 
reported for other positively charged peptides [45], such as LL37 fragments [46]
 
and CRAMP [47].
 
 
Finally, we wanted to assess whether SET-M33 and Q-33 had the same ability to adopt a helix 
conformation in a membrane mimicking environment, using circular dichroism. The technique 
proved to be applicable to both the tetrabranched and the linear peptide. SET-M33 and Q-33 CD 
spectra were recorded at room temperature in water and in SDS 30 mM. In line with the NMR 
experiments, SET-M33 showed a non-structured conformation in water but the CD spectrum shifted 
sharply to longer wavelengths in the presence of SDS micelles (Figure 5C), and the calculated helix 
ratio switched from 0% to 30%. A similar result was obtained with Q-33 (Figure 5D): the spectra 
recorded in water had a calculated helix ratio of 3.3% compared to 39% in the presence of SDS 
micelles. The CD spectra of SET-M33 and Q-33, recorded with or without micelles, were very 
similar, confirming that Q-33 was a reliable model of SET-M33 for the NMR experiments.  
 
Selectivity / hemolytic activity 
The ability of cationic peptides to stabilize as an α-helix, and particularly as a facial amphiphilic 
structure, is often associated with self-aggregation and undesired peptide interactions with blood 
proteins due to exposed hydrophobic surfaces [45]. The tendency to self-aggregate is correlated to 
hydrophobicity and provides an indirect estimate of the propensity for partitioning into lipid 
membranes with unselective detergent-like characteristics. Antimicrobial peptides need to be 
selective for prokaryotic membranes; a well-established method of verifying their ability to damage 
eukaryotic cell membranes is to measure their hemolytic activity [48]. Our results showed that red 
blood cells incubated with increasing concentrations of SET-M33 did not show more than 26% 
lysis, even using a concentration of 1.8 mg/ml (320 µM), which is more than 100-fold the MIC 
(Figure 6). 
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Figure 6. Hemolytic activity of SET-M33. Percentage of red blood cell hemolysis after 24 h 
incubation at 37
o
C. The range of MIC90 for K. pneumoniae and P. aeruginosa is indicated.  
 
In contrast with other cationic peptides [49], SET-M33 showed very little hemolytic activity against 
red blood cells, although it shares the ability to form a regular α-helix shape. Indeed, SET-M33 also 
proved not to be cytotoxic to human bronchial epithelial cells (16HBE14 and CFBE41) [23]. Self-
aggregation, often associated with amphiphilic structures and undesired secondary effects [49], was 
also studied in FPLC experiments (Supplementary material – Figure 1S, A) and showed that no 
self-aggregation occurred when SET-M33 was dissolved in PBS. The presence of LPS promoted 
the formation of high-mass hetero-multimers, but not homo-multimers (Supplementary material – 
Figure 1S, B), in line with what we observed and described above in relation to SDS.  
 
Conclusions 
Current understanding of the mechanism of action of cationic AMPs includes a first step of 
electrostatic attraction between the cationic peptide and the negatively charged bacterial outer 
membrane. As SET-M33 is a cationic amphiphilic peptide it is attracted to the negatively charged 
bacterial membrane. Once close to the microbial surface, AMPs need to cross the polysaccharide 
cell wall barrier before interacting with the cytoplasmic membrane [15, 50-51]. In line with this, in 
previous studies, SET-M33 was shown, by surface plasmon resonance, to bind LPS of K. 
pneumoniae and P. aeruginosa [52] and the binding prevented TNF- release, neutralizing  
endotoxin activity in vitro and in vivo [22, 41]. In the present study, NMR investigation of Q-
33/SDS micelles in solution and in the presence of a paramagnetic probe showed that the α-helix 
arranges itself on the surface of micelles as previously described for other antimicrobial peptides 
[53-55]. Though direct measurement of the geometry of SET-M33/SDS micelle interactions was 
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not possible, we demonstrated with CD that the structural transition observed using Q-33/SDS 
micelles also occurs using the original tetra-branched SET-M33 peptide. The α-helix showed to be 
partially buried in the lipid-bilayer. In the course of 15-60 minutes, the signs of membrane damages 
are, indeed, evident in electron microscopy. We also knew that SET-M33 is internalized in E. Coli 
within 5 minutes, proving that it can cross cell wall and plasma membranes [41], causing enhanced 
membrane permeability, as observed with fluorescent probes [41]. Bacteria death may realistically 
be caused by impairment of the membrane homeostasis and functionality.  
Interestingly, SET-M33 is different from other α-helix antimicrobial peptides in that it shows little 
propensity to self-aggregate and also no hemolytic activity. Homo-aggregation, which is considered 
related with undesired toxicity [48-49], is never observed. This aspect probably contributes in 
preventing non-specific interactions with eukaryotic cells [48-49] and indeed correlates with an 
acceptable tolerability profile obtained in toxicology studies in mice [21]. 
SET-M33 does not show any cross-resistance with colistin in colistin-resistant bacteria and, 
differently from colistin, it appears to generate substantially no resistance within 24 hours of 
exposure in extensively resistant isolates of K. pneumoniae and P. aeruginosa. These observations 
suggest that the two peptides have a different mechanism of action. SET-M33 is attracted onto the 
surface of bacteria by the anionic charges of the cell wall. Being the core of the branched peptide 
completely flexible, we speculate that in the presence of phospholipid-bilayers, the peptide can 
assume a star like conformation, where hydrophobic residues are buried in the surface and 
hydrophilic residues point outwards. The disturbance of bi-layers integrity, produced by SET-
M33’s peculiar way to interact with membranes, makes it more difficult for bacteria to trigger 
resistance mechanisms than it is for colistin. 
Finally SET-M33, in contrast to other similar antimicrobial peptides such as colistin, does not 
generate resistant mutants after 24 h of exposure, and non-specific interactions or toxicity against 
eukaryotic cell membranes, suggesting that SET-M33 is a promising new option for the treatment 
of Gram-negative antibiotic-resistant infections. 
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Highlights 
 
 SET-M33, an antimicrobial branched peptide, is active against colistin-resistant Gram 
negative bacteria 
 It adopts a -helix conformation in a membrane mimicking environment 
 It shows little toxicity against eukaryotic cells and acts without selection of resistant clones 
within 24 hours. 
